These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156 [TBL] [Abstract][Full Text] [Related]
5. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. Yang C; Pan X; Xu X; Cheng C; Huang Y; Li L; Jiang S; Xu W; Xiao G; Liu S Signal Transduct Target Ther; 2020 Oct; 5(1):220. PubMed ID: 33024075 [No Abstract] [Full Text] [Related]
9. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
10. Overview of lethal human coronaviruses. Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062 [TBL] [Abstract][Full Text] [Related]
11. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094 [TBL] [Abstract][Full Text] [Related]
12. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096 [TBL] [Abstract][Full Text] [Related]
13. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Poduri R; Joshi G; Jagadeesh G Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111 [TBL] [Abstract][Full Text] [Related]
14. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926 [TBL] [Abstract][Full Text] [Related]
15. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight. Nicolau LAD; Nolêto IRSG; Medeiros JVR Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527 [No Abstract] [Full Text] [Related]
16. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122 [TBL] [Abstract][Full Text] [Related]
17. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968 [TBL] [Abstract][Full Text] [Related]
18. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. Li SR; Tang ZJ; Li ZH; Liu X Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840 [TBL] [Abstract][Full Text] [Related]
20. Purposing Saikosaponins for the treatment of COVID-19. Bahbah EI; Negida A; Nabet MS Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743 [No Abstract] [Full Text] [Related] [Next] [New Search]